D 824

Drug Profile

D 824

Alternative Names: D824; GZD 824

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Class Benzamides; Heterocyclic compounds; Piperazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic myeloid leukaemia

Highest Development Phases

  • No development reported Chronic myeloid leukaemia

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Chronic-myeloid-leukaemia in China (PO, Tablet)
  • 10 Aug 2016 Chemical structure information added
  • 26 Jul 2016 D 824 is available for licensing in North America, European Union (excluding China) as of 26 Jul 2016. (http://english.gibh.cas.cn)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top